These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emerging therapies in the long-term management of hyperuricaemia and gout. Stamp LK; O'Donnell JL; Chapman PT Intern Med J; 2007 Apr; 37(4):258-66. PubMed ID: 17388867 [TBL] [Abstract][Full Text] [Related]
4. [Hyperuricemia and Gout]. Delbarba E; Terlizzi V; Dallera N; Izzi C; Scolari F G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960024 [TBL] [Abstract][Full Text] [Related]
5. Current and future therapeutic options for the management of gout. Whelton A Am J Ther; 2010; 17(4):402-17. PubMed ID: 20562597 [TBL] [Abstract][Full Text] [Related]
6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265 [TBL] [Abstract][Full Text] [Related]
7. Update on gout and hyperuricemia. Baker JF; Schumacher HR Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378 [TBL] [Abstract][Full Text] [Related]
9. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Sherman MR; Saifer MG; Perez-Ruiz F Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865 [TBL] [Abstract][Full Text] [Related]
11. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Hamburger M; Baraf HS; Adamson TC; Basile J; Bass L; Cole B; Doghramji PP; Guadagnoli GA; Hamburger F; Harford R; Lieberman JA; Mandel DR; Mandelbrot DA; McClain BP; Mizuno E; Morton AH; Mount DB; Pope RS; Rosenthal KG; Setoodeh K; Skosey JL; Edwards NL Phys Sportsmed; 2011 Nov; 39(4):98-123. PubMed ID: 22293773 [TBL] [Abstract][Full Text] [Related]
12. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270 [TBL] [Abstract][Full Text] [Related]
13. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Bruce SP Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810 [TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Becker MA Rheum Dis Clin North Am; 1988 Aug; 14(2):377-94. PubMed ID: 3051156 [TBL] [Abstract][Full Text] [Related]
15. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis. Perez-Ruiz F; Herrero-Beites AM; Carmona L Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351 [TBL] [Abstract][Full Text] [Related]
16. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094 [TBL] [Abstract][Full Text] [Related]
17. [Gout as a systemic disease: systemic manifestations and comorbidities of hyperuricaemia]. Glasnović M Reumatizam; 2012; 59(2):119-32. PubMed ID: 23745468 [TBL] [Abstract][Full Text] [Related]